🇫🇷 France Country × Condition
ovarian cancer Clinical Trials in France
Active clinical trials for ovarian cancer with research sites in France. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 Phases: Phase 2, Phase 1, Phase 2 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇫🇷 France
Active Trials in France (5)
NCT06216496
Recruiting
Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer
Enrollment
23 pts
Country
🇫🇷 France
University Hospital, Grenoble
View Trial → NCT03787056
Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Enrollment
410 pts
Country
🇫🇷 France
Hospices Civils de Lyon
View Trial → NCT06152731 Phase 2
Recruiting
HRD Tests for Ovarian cancER
Enrollment
88 pts
Country
🇫🇷 France
Centre Francois Baclesse
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇫🇷 France
PMV Pharmaceuticals, Inc
View Trial → NCT01977274
Recruiting
Predictive Clinical and Biological Parameters in Gynecological Cancer
Enrollment
300 pts
Country
🇫🇷 France
Institut Paoli-Calmettes
View Trial → Frequently Asked Questions
How many ovarian cancer clinical trials are active in France?
There are currently 5 active clinical trials for ovarian cancer with sites in France, of which 5 are actively recruiting patients.
How can I join a ovarian cancer clinical trial in France?
To join a ovarian cancer clinical trial in France, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in France directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are ovarian cancer trials in France?
Active ovarian cancer trials in France span Phase 2, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.